Treating Colorectal Cancer with Immunotherapy: Implications for Single versus Combination Therapy.

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Colorectal cancer (CRC) is a leading cause of cancer deaths in the US.
• Metastatic CRC often becomes resistant to conventional chemotherapy.
• Immunotherapy offers a promising approach by leveraging the immune system to combat cancer cells.

Purpose of the Study:

• To review the efficacy of single versus combination immunotherapy for CRC.
• To identify molecular features and mutations influencing immunotherapy response.
• To understand factors that enhance or impede treatment effectiveness.

Main Methods:

• Literature review of current research on immunotherapy in CRC.
• Analysis of molecular markers associated with treatment outcomes.
• Comparison of single-agent immunotherapy, combination immunotherapy, and chemotherapy.

Main Results:

• Responsiveness to immunotherapy correlates with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-high) status.
• High immunoscore and tumor mutational burden (TMB) indicate better efficacy.
• BRAF mutations did not show a significant impact on response.
• Combination immunotherapy outperformed single-agent immunotherapy and chemotherapy in MSI-high CRC.

Conclusions:

• Immunotherapy has the potential to become a new standard of care for metastatic CRC.
• Patient stratification based on molecular features and mutation status is crucial for optimizing treatment.
• Improved responsiveness and overall survival support the use of immunotherapy.